Please login to the form below

Hanover Health launches the Mackay Programme

New programme for communicators looking to breakthrough in their careers.

Hanover Health has today launched The Mackay Programme to offer experienced professionals the opportunity to switch careers by joining an award-winning healthcare communications consultancy that helps to change the lives of millions for the better.

The programme, open to non-healthcare agency professionals and experienced communicators working in the wider healthcare sector, will provide comprehensive training and development to help propel successful candidates into a global healthcare communications career.

The selected candidates will join the Hanover Health team, who provide smart thinking, refreshing storytelling and breakthrough solutions to a wide range of global clients including: pharmaceutical and medical technology companies, healthcare service providers, charities, professional and public-sector bodies.

The programme will include:

· Fundamental training on our company, our services, our healthcare offer and how the business is run

· Industry-recognised training opportunities and participation in our Hanover Academy training programme

· Investment and budget to spend on CPD or professional qualifications to further career development

· Attendance at industry conferences and events

· The ability to draw on our network of experts in the sector (the Hanover Group is part of AVENIR GLOBAL, a global network of comms and public affairs consultancies)

· Opportunities to work with colleagues in our Brussels, Dublin and Middle East offices

· Immersion within an entrepreneurial environment

· Hanover Group benefits and additional perks

Successful candidates will be placed at levels ranging from Consultant up to Associate Director.

This opportunity is suited to those with a passion for communications and a drive to join a fast-paced, breakthrough industry.

Applicants must be able to demonstrate strong communications skills and an interest in the sector but no prior experience in healthcare is necessary. Applications close: Friday 10th April 2020. Shortlisted candidates will be invited to interview at the Hanover office in London.

The Mackay programme is dedicated to one of Hanover’s founders, Gregor Mackay, who died in 2005 eight weeks after being diagnosed with a rare form of cancer. Mackay personified an “uncommon sense” approach and took particular interest in the development of people and teams.

Andrew Harrison, Managing Director of Hanover Health, said:

“At Hanover Health, we recognise that the best innovation and creative problem-solving requires diverse thinking.

This is why we’re looking for the brightest minds across communications, public affairs and healthcare, to help bring fresh thinking, bold ideas and broad experience into the industry. The sector is constantly evolving, and this opportunity offers a different cohort of talent the chance to be part of this change, working with clients who are on the cusp of the latest research and technology to improve lives for the better.

It is only fitting to name it after Gregor Mackay, a man who personified the breakthrough approach, and who recognised the transformational power of great communications.”

For more information and to apply please visit www.hanovercomms.com or contact recruitment@hanovercomms.com.

-ends-

NOTES TO EDITORS

  1. Hanover Health’s team provides product and corporate communications, market access, policy and public affairs at an international and local level from its offices in London, Brussels, Dublin, Dubai and Abu Dhabi. Hanover Health is part of the wider Hanover Group. Hanover Group is part of the AVENIR GLOBAL group of companies. More information can be found at www.hanovercomms.com.

2. Hanover Health works with over half of the world’s top 20 pharmaceutical companies, as well as health technology businesses, trade associations, charities and healthcare providers. The fast-growing practice has been an important part of the Hanover Group’s overall expansion – a 25% average annual growth rate for the last five years.

3. Hanover Health won three prestigious industry awards in 2019: PharmaTimes International Team of the Year, EMEA Sabre Medical Technology and PRWeek Awards: Issues and Reputation Management.

4. Hanover Health is chaired by Sarah Matthew, co-founder of Virgo Health and one of the most influential figures in healthcare communications.

11th February 2020

Share

Tags

Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Address:
70 Gray's Inn Road
London
WC1X 8BT
United Kingdom

Latest content on this profile

Why it’s in everyone’s interest the Women’s Health Strategy for England succeeds
Timed to coincide with International Women’s Day, the Government’s Women’s Health Strategy for England landed at a moment of national contemplation about women’s place in society more generally, following the murder of Sarah Everard. In her latest blog, Hanover Health’s Jennifer Blainey breaks down the strategy and considers what needs to happen for it to succeed.
Hanover Communications
COVID-19 has changed the way we must talk about treatment for rare diseases
The turbulence of the last year has brought into sharp focus the difficult choices to be made when it comes to healthcare prioritisation. There is now more of a reluctant acceptance that there will always be someone or something that will miss out so the ‘unjust’ emotional argument won’t resonate in the same way anymore. In her latest blog, Hanover Health’s Emma Gorton considers why in the wake of Covid-19, communicators must change their narrative around the treatment of rare diseases.
Hanover Communications
What does the COVID-19 vaccine mean for the future of R&D?
Amid a pandemic, time is a luxury the world cannot afford. The last 12 months have contradicted what we once thought about the speed of progressing scientific research. Here Shannon Lacombe explores the factors that have contributed to the unprecedented speed of vaccine development from early-stage research to mass public rollout. She also looks at what precedent this has set for the future of research and development timelines and the assumptions and status quo that will now be challenged as a result.
Hanover Communications
Is the world ready for a COVID-19 vaccine?
At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection. Since then, other good news has followed, with collaborations, including Moderna and AstraZeneca, publishing similarly positive results. This is a phenomenal feat that would have been unimaginable just one year ago. But a vaccine is only as effective as its deployment and uptake. There should be no doubt that as soon as the first COVID-19 vaccine was approved, a very difficult logistics game ensued. The reality is that a COVID-19 vaccine will present a whole new unfamiliar set of operational challenges. There are currently more than 170 candidate vaccines in development, each with its own benefits and each with its own challenges. Here, we explore some of those challenges and reflect on what must be considered by health systems and governments to set us on track towards pandemic recovery.
Hanover Communications
It's out - so what?
The European Commission’s Pharmaceutical Strategy has been published and the Commission has presented its priorities for the coming years. The focus is on patient access to affordable treatments; ensuring and boosting the competitiveness of the European pharmaceutical sector and making sure that the EU will have a strong voice on global health and pharmaceutical policy. Stakeholders now need to make sure that their voices are heard and included in upcoming proposals and, eventually, in legislation. By Jenni Kortelainen, Hanover EU
Hanover Communications
Let's be ambitious for patients and life sciences investment in Global Britain
“Take up of new medicines in the UK continues to be slow by international standards”. Since this Pharmaceutical Industry Competitiveness Task Force report in 2005, there have been at least five UK life science strategies plus three PPRS or VPAS deals. All have promised to accelerate access of new medicines to patients. Sadly, 12 years on, the 2017 Life Sciences Industrial Strategy could only restate the challenge: “Evidence demonstrates that access to and diffusion of products in the NHS is often slower than in some comparable countries”. Can we ever break this cycle? By Andrew Harrison, Group Managing Director of Hanover Health.
Hanover Communications